Unit
Brustzentrum St.Gallen
BZ · Dept. IV
Patterns of care for patients with metastatic bone disease in solid tumors: A cross-sectional study from Switzerland (SAKK 95/16)
Mark M, Caspar C, Mannhart M, von Burg P, Blum V, Bohanes P, Anchisi S, von Briel T, Zürrer-Härdi U, Cathomas R, Dietrich D, Schär C, Ribi K, Thürlimann B, von Moos R. Patterns of care for patients with metastatic bone disease in solid tumors: A cross-sectional study from Switzerland (SAKK 95/16). J Bone Oncol 2019; 21:100273.
Dec 16, 2019Patterns of care for patients with metastatic bone disease in solid tumors: A cross-sectional study from Switzerland (SAKK 95/16)
Dec 16, 2019J Bone Oncol 2019; 21:100273
Mark Michael, Caspar Clemens B, Mannhart Meinrad, von Burg Philipp, Blum Veronika, Bohanes Pierre, Anchisi Sandro, von Briel Thomas, Zürrer-Härdi Ursina, Cathomas Richard, Dietrich Daniel, Schär Corinne, Ribi Karin, Thürlimann Beat, von Moos Roger
An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06)
Risi E, Di Leo A, Biganzoli L, Sotiriou C, Vitale S, Boccalini G, Romagnoli D, Huober J, Di Cosimo S, Hilbers F, Guarducci C, Bonechi M, McCartney A, Migliaccio I, Benelli M, Biagioni C, Malorni L. An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06). Ther Adv Med Oncol 2019; 11:1758835919891608.
Dec 11, 2019An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06)
Dec 11, 2019Ther Adv Med Oncol 2019; 11:1758835919891608
Risi Emanuela, Di Leo Angelo, Biganzoli Laura, Sotiriou Christos, Vitale Stefania, Boccalini Giulia, Romagnoli Dario, Huober Jens, Di Cosimo Serena, Hilbers Florentine, Guarducci Cristina, Bonechi Martina, McCartney Amelia, Migliaccio Ilenia, Benelli Matteo, Biagioni Chiara, Malorni Luca
Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy
Sinn B, Denkert C, Seliger B, von Minckwitz G, Huober J, Ataseven B, Stickeler E, Schem C, Marme F, Klauschen F, Taube E, Karn T, Blohmer J, Symmans W, Fasching P, Schmitt W, Weber K, Loibl S. Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy. Breast Cancer Res 2019; 21:142.
Dec 11, 2019Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy
Dec 11, 2019Breast Cancer Res 2019; 21:142
Sinn Bruno Valentin, Denkert Carsten, Seliger Barbara, von Minckwitz Gunter, Huober Jens, Ataseven Beyhan, Stickeler Elmar, Schem Christian, Marme Frederik, Klauschen Frederick, Taube Eliane Tabea, Karn Thomas, Blohmer Jens-Uwe, Symmans William Fraser, Fasching Peter A, Schmitt Wolfgang Daniel, Weber Karsten E, Loibl Sibylle
Corrections to "De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017"
Curigliano G, Thürlimann B, Senn H, Piccart-Gebhart M, Regan M, Colleoni M, Loibl S, Dubsky P, Gnant M, P Winer E, Burstein H, Panel Members of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017. Corrections to "De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017". Ann Oncol 2019; 30:1181.
Dec 4, 2019Corrections to "De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017"
Dec 4, 2019Ann Oncol 2019; 30:1181
Curigliano G, Thürlimann Beat, Senn H-J, Piccart-Gebhart M, Regan M M, Colleoni M, Loibl S, Dubsky P, Gnant M, P Winer E, Burstein H J, Panel Members of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017
Reply to Does the expert panel at the St Gallen meeting provide an unbiased opinion about the management of women with early breast cancer?
Coates A, Goldhirsch A, Gelber R, Ingle J, Thürlimann B, Senn H. Reply to Does the expert panel at the St Gallen meeting provide an unbiased opinion about the management of women with early breast cancer?. Ann Oncol 2019; 20:1751-1752.
Dec 4, 2019Reply to Does the expert panel at the St Gallen meeting provide an unbiased opinion about the management of women with early breast cancer?
Dec 4, 2019Ann Oncol 2019; 20:1751-1752
Coates A S, Goldhirsch A, Gelber R D, Ingle J N, Thürlimann Beat, Senn H-J
Feasibility of a large multi-center translational research project for newly diagnosed breast and ovarian cancer patients with affiliated biobank: the BRandO biology and outcome (BiO)-project
De Gregorio A, Rothenbacher D, Janni W, Schmitt M, Kuhn P, Wiesmüller L, Friedl T, De Gregorio N, Ebner F, Felberbaum R, Thiel F, Kühn T, Flock F, Fritz S, Schlicht E, Rempen A, Möller P, Nagel G, Huober J. Feasibility of a large multi-center translational research project for newly diagnosed breast and ovarian cancer patients with affiliated biobank: the BRandO biology and outcome (BiO)-project. Arch Gynecol Obstet 2019; 301:273-281.
Nov 28, 2019Feasibility of a large multi-center translational research project for newly diagnosed breast and ovarian cancer patients with affiliated biobank: the BRandO biology and outcome (BiO)-project
Nov 28, 2019Arch Gynecol Obstet 2019; 301:273-281
De Gregorio Amelie, Rothenbacher Dietrich, Janni Wolfgang, Schmitt Margit, Kuhn Peter, Wiesmüller Lisa, Friedl Thomas Wolfram Paul, De Gregorio Nikolaus, Ebner Florian, Felberbaum Ricardo, Thiel Falk, Kühn Thorsten, Flock Felix, Fritz Steffen, Schlicht Erik, Rempen Andreas, Möller Peter, Nagel Gabriele, Huober Jens
Sequential somatic mutations upon secondary anti-HER2 treatment resistance in metastatic ERBB2 mutated extramammary Paget's disease.
Nordmann T, Messerli-Odermatt O, Meier L, Micaletto S, Coppetti T, Nägeli M, Kamarachev J, Kudura K, Freiberger S, Rordorf T, Mangana J, Braun R, Dummer R. Sequential somatic mutations upon secondary anti-HER2 treatment resistance in metastatic ERBB2 mutated extramammary Paget's disease. Oncotarget 2019; 10:6647-6650.
Nov 19, 2019Sequential somatic mutations upon secondary anti-HER2 treatment resistance in metastatic ERBB2 mutated extramammary Paget's disease.
Nov 19, 2019Oncotarget 2019; 10:6647-6650
Nordmann Thierry M, Messerli-Odermatt Olivia, Meier Larissa, Micaletto Sara, Coppetti Thomas, Nägeli Mirjam, Kamarachev Jivko, Kudura Ken, Freiberger Sandra N, Rordorf Tamara, Mangana Joanna, Braun Ralph, Dummer Reinhard
Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial
Witzel I, Untch M, Stickeler E, Schem C, Marme F, Mackelenbergh M, Karn T, Huober J, Lück H, Weber K, Denkert C, Fasching P, Wirtz R, Loibl S, Müller V. Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial. Br J Cancer 2019; 121:1009-1015.
Nov 15, 2019Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial
Nov 15, 2019Br J Cancer 2019; 121:1009-1015
Witzel Isabell, Untch Michael, Stickeler Elmar, Schem Christian, Marme Frederik, Mackelenbergh Marion von, Karn Thomas, Huober Jens, Lück Hans-Joachim, Weber Karsten, Denkert Carsten, Fasching Peter A, Wirtz Ralph, Loibl Sibylle, Müller Volkmar
Are Circulating Tumor Cells (CTCs) Ready for Clinical Use in Breast Cancer? An Overview of Completed and Ongoing Trials Using CTCs for Clinical Treatment Decisions
Schochter F, Friedl T, deGregorio A, Krause S, Huober J, Rack B, Janni W. Are Circulating Tumor Cells (CTCs) Ready for Clinical Use in Breast Cancer? An Overview of Completed and Ongoing Trials Using CTCs for Clinical Treatment Decisions. Cells 2019; 8
Nov 8, 2019Are Circulating Tumor Cells (CTCs) Ready for Clinical Use in Breast Cancer? An Overview of Completed and Ongoing Trials Using CTCs for Clinical Treatment Decisions
Nov 8, 2019Cells 2019; 8
Schochter Fabienne, Friedl Thomas W P, deGregorio Amelie, Krause Sabrina, Huober Jens, Rack Brigitte, Janni Wolfgang
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Burtness B, Harrington K, Greil R, Soulières D, Tahara M, de Castro G, Psyrri A, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes B, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak W, Hong R, González Mendoza R, Roy A, Zhang Y, Gumuscu B, Cheng J, Jin F, Rischin D, ĀăąĆĉČĎ Ā. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 2019; 394:1915-1928.
Nov 1, 2019Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Nov 1, 2019Lancet 2019; 394:1915-1928
Burtness Barbara, Harrington Kevin J, Greil Richard, Soulières Denis, Tahara Makoto, de Castro Gilberto, Psyrri Amanda, Basté Neus, Neupane Prakash, Bratland Åse, Fuereder Thorsten, Hughes Brett G M, Mesia Ricard, Ngamphaiboon Nuttapong, Rordorf Tamara, Wan Ishak Wan Zamaniah, Hong Ruey-Long, González Mendoza René, Roy Ananya, Zhang Yayan, Gumuscu Burak, Cheng Jonathan D, Jin Fan, Rischin Danny, ĀăąĆĉČĎ Ā ā Ă ă Ą ą Ć ć Ĉ ĉ Ċ ċ Č č Ď ď Đ đ Ē ē Ĕ ĕ Ė ė Ę ę Ě ě Ĝ ĝ Ğ ğ Ġ ġ Ģ ģ Ĥ ĥ Ħ ħ Ĩ ĩ Ī ī Ĭ ĭ Į į İ ı IJ ij Ĵ ĵ Ķ ķ ĸ Ĺ ĺ Ļ ļ Ľ ľ Ŀ ŀ Ł ł Ń ń Ņ ņ Ň ň ʼn Ŋ ŋ Ō ō Ŏ ŏ Ő ő Œ œ Ŕ ŕ Ŗ ŗ Ř ř Ś ś Ŝ ŝ Ş ş Š š Ţ ţ Ť ť Ŧ ŧ Ũ ũ Ū ū Ŭ ŭ Ů ů Ű ű Ų ų Ŵ ŵ Ŷ ŷ Ÿ Ź ź Ż ż Ž ž ſ
Influence of the New FIGO Classification for Cervical Cancer on Patient Survival: A Retrospective Analysis of 265 Histologically Confirmed Cases with FIGO Stages IA to IIB
De Gregorio A, Widschwendter P, Ebner F, Friedl T, Huober J, Janni W, De Gregorio N. Influence of the New FIGO Classification for Cervical Cancer on Patient Survival: A Retrospective Analysis of 265 Histologically Confirmed Cases with FIGO Stages IA to IIB. Oncology 2019; 98:91-97.
Oct 8, 2019Influence of the New FIGO Classification for Cervical Cancer on Patient Survival: A Retrospective Analysis of 265 Histologically Confirmed Cases with FIGO Stages IA to IIB
Oct 8, 2019Oncology 2019; 98:91-97
De Gregorio Amelie, Widschwendter Peter, Ebner Florian, Friedl Thomas Wolfram Paul, Huober Jens, Janni Wolfgang, De Gregorio Nikolaus
Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: Results from the phase III BrighTNess trial
Golshan M, Sikov W, Geyer C, von Minckwitz G, Metzger-Filho O, Sullivan D, Maag D, Ansell P, Wolmark N, Rugo H, O'Shaughnessy J, Huober J, Loibl S, Wong S, Untch M. Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: Results from the phase III BrighTNess trial. Eur J Surg Oncol 2019; 46:223-228.
Oct 5, 2019Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: Results from the phase III BrighTNess trial
Oct 5, 2019Eur J Surg Oncol 2019; 46:223-228
Golshan Mehra, Sikov William M, Geyer Charles E, von Minckwitz Gunter, Metzger-Filho Otto, Sullivan Danielle M, Maag David, Ansell Peter, Wolmark Norman, Rugo Hope S, O'Shaughnessy Joyce, Huober Jens, Loibl Sibylle, Wong Stephanie M, Untch Michael
Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019
Burstein H, Thürlimann B, Winer E, Senn H, Regan M, Piccart-Gebhart M, Denkert C, Colleoni M, Poortmans P, Gnant M, Dubsky P, Loibl S, Curigliano G, Members of the St. Gallen International Consensus Panel on the Primary Therapy of Early Breast Cancer 2019. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol 2019; 30:1541-1557.
Oct 1, 2019Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019
Oct 1, 2019Ann Oncol 2019; 30:1541-1557
Burstein H J, Thürlimann Beat, Winer E P, Senn H-J, Regan M, Piccart-Gebhart M, Denkert C, Colleoni M, Poortmans P, Gnant M, Dubsky P, Loibl S, Curigliano G, Members of the St. Gallen International Consensus Panel on the Primary Therapy of Early Breast Cancer 2019
Ki-67 assessment in early breast cancer: SAKK28/12 validation study on the IBCSG VIII and IBCSG IX cohort
Varga Z, Thürlimann B, Klingbiel D, Hawle H, Tille J, Rau T, Perriard U, Jochum W, Li Q, Ruhstaller T. Ki-67 assessment in early breast cancer: SAKK28/12 validation study on the IBCSG VIII and IBCSG IX cohort. Sci Rep 2019; 9:13534.
Sep 19, 2019Ki-67 assessment in early breast cancer: SAKK28/12 validation study on the IBCSG VIII and IBCSG IX cohort
Sep 19, 2019Sci Rep 2019; 9:13534
Varga Zsuzsanna, Thürlimann Beat, Klingbiel Dirk, Hawle Hanne, Tille Jean-Christoph, Rau Tilman, Perriard Ulrike, Jochum Wolfram, Li Qiyu, Ruhstaller Thomas
Treatment of Early Breast Cancer Patients: Evidence, Controversies, Consensus: Focusing on Systemic Therapy - German Experts' Opinions for the 16th International St. Gallen Consensus Conference (Vienna 2019)
Luftner D, Kolberg-Liedtke C, Kühn T, Maass N, Reimer T, Schneeweiss A, Schumacher-Wulf E, Schütz F, Thomssen C, Untch M, Wuerstlein R, Kolberg H, Jackisch C, Bauerfeind I, Braun M, Brucker S, Fasching P, Felberbaum R, Hagemann F, Haidinger R, Harbeck N, Hönig A, Huober J, Thill M. Treatment of Early Breast Cancer Patients: Evidence, Controversies, Consensus: Focusing on Systemic Therapy - German Experts' Opinions for the 16th International St. Gallen Consensus Conference (Vienna 2019). Breast Care (Basel) 2019; 14:315-324.
Sep 17, 2019Treatment of Early Breast Cancer Patients: Evidence, Controversies, Consensus: Focusing on Systemic Therapy - German Experts' Opinions for the 16th International St. Gallen Consensus Conference (Vienna 2019)
Sep 17, 2019Breast Care (Basel) 2019; 14:315-324
Luftner Diana, Kolberg-Liedtke Cornelia, Kühn Thorsten, Maass Nicolai, Reimer Toralf, Schneeweiss Andreas, Schumacher-Wulf Eva, Schütz Florian, Thomssen Christoph, Untch Michael, Wuerstlein Rachel, Kolberg Hans-Christian, Jackisch Christian, Bauerfeind Ingo, Braun Michael, Brucker Sara Y, Fasching Peter A, Felberbaum Ricardo, Hagemann Friederike, Haidinger Renate, Harbeck Nadia, Hönig Arnd, Huober Jens, Thill Marc
Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy
Panje C, Plasswilm L, Ruhstaller T, Gerard M, Hawle H, Schacher S, Henke G, Meier U, Garcia Schüler H, Herrmann E, Baracos V, Hayoz S, Höng L, Swiss Group for Clinical Cancer Research (SAKK). Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy. Radiat Oncol 2019; 14:166.
Sep 11, 2019Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy
Sep 11, 2019Radiat Oncol 2019; 14:166
Panje Cédric, Plasswilm Ludwig, Ruhstaller Thomas, Gerard Marie-Aline, Hawle Hanne, Schacher Sabina, Henke Guido, Meier Urs R, Garcia Schüler Helena, Herrmann Evelyn, Baracos Vickie E, Hayoz Stefanie, Höng Laura, Swiss Group for Clinical Cancer Research (SAKK)
Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data
Schmid S, Zaman K, Weder P, von Moos R, Thürlimann B, Rochlitz C, Pestalozzi B, Pagani O, Oehlschlegel C, Nolè F, Munzone E, Mamot C, Goldhirsch A, Aebi S, Klingbiel D, Ruhstaller T. Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data. BMC cancer 2019; 19:902.
Sep 10, 2019Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data
Sep 10, 2019BMC cancer 2019; 19:902
Schmid Sabine, Zaman Khalil, Weder Patrik, von Moos Roger, Thürlimann Beat, Rochlitz Christoph, Pestalozzi Bernhard, Pagani Olivia, Oehlschlegel Christian, Nolè Franco, Munzone Elisabetta, Mamot Christoph, Goldhirsch Aron, Aebi Stefan, Klingbiel Dirk, Ruhstaller Thomas
Independent Validation of EarlyR Gene Signature in BIG 1-98: A Randomized, Double-Blind, Phase III Trial Comparing Letrozole and Tamoxifen as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive, Early Breast Cancer
Buechler S, Badve S, Leyland-Jones B, Viale G, Kammler R, Thürlimann B, Willis S, Gökmen-Polar Y, Gray K, Regan M. Independent Validation of EarlyR Gene Signature in BIG 1-98: A Randomized, Double-Blind, Phase III Trial Comparing Letrozole and Tamoxifen as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive, Early Breast Cancer. JNCI Cancer Spectr 2019; 3:pkz051.
Aug 16, 2019Independent Validation of EarlyR Gene Signature in BIG 1-98: A Randomized, Double-Blind, Phase III Trial Comparing Letrozole and Tamoxifen as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive, Early Breast Cancer
Aug 16, 2019JNCI Cancer Spectr 2019; 3:pkz051
Buechler Steven A, Badve Sunil S, Leyland-Jones Brian, Viale Giuseppe, Kammler Rosita, Thürlimann Beat, Willis Scooter, Gökmen-Polar Yesim, Gray Kathryn P, Regan Meredith M
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019
Wöckel A, Rhiem K, Nitz U, Mundhenke C, Müller-Schimpfle M, Möbus V, Maass N, Lux M, Luftner D, Loibl S, Rody A, Schmidt M, Witzel I, Wenz F, Thomssen C, Stickeler E, Solomayer E, Solbach C, Sinn H, Schütz F, Schneeweiss A, Kümmel S, Kühn T, Krug D, Dall P, Budach W, Blohmer J, Bauerfeind I, Albert U, Janni W, Müller V, Thill M, Untch M, Diel I, Fasching P, Kreipe H, Kolberg-Liedtke C, Jackisch C, Huober J, Harbeck N, Hanf V, Gerber B, Friedrich M, Fehm T, Ditsch N. AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019. Breast Care (Basel) 2019; 14:224-245.
Aug 6, 2019AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019
Aug 6, 2019Breast Care (Basel) 2019; 14:224-245
Wöckel Achim, Rhiem Kerstin, Nitz Ulrike, Mundhenke Christoph, Müller-Schimpfle Markus, Möbus Volker, Maass Nicolai, Lux Michael Patrick, Luftner Diana, Loibl Sibylle, Rody Achim, Schmidt Marcus, Witzel Isabell, Wenz Frederik, Thomssen Christoph, Stickeler Elmar, Solomayer Erich-Franz, Solbach Christine, Sinn Hans-Peter, Schütz Florian, Schneeweiss Andreas, Kümmel Sherko, Kühn Thorsten, Krug David, Dall Peter, Budach Wilfried, Blohmer Jens, Bauerfeind Ingo, Albert Ute-Susann, Janni Wolfgang, Müller Volkmar, Thill Marc, Untch Michael, Diel Ingo, Fasching Peter A, Kreipe Hans-Heinrich, Kolberg-Liedtke Cornelia, Jackisch Christian, Huober Jens, Harbeck Nadia, Hanf Volker, Gerber Bernd, Friedrich Michael, Fehm Tanja, Ditsch Nina
Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer
Huober J, Hackman J, Dasappa L, Ciruelos E, Toral Pena J, Adamchuk H, Hickish T, de la Pena L, Jackisch C, Gelber R, Piccart-Gebhart M, Jouannaud C, Wildiers H, Lecocq C, Holmes E, Baselga J, de Azambuja E, Untch M, Fumagalli D, Sarp S, Láng I, Smith I, Boyle F, Xu B, Di Cosimo S. Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer. Eur J Cancer 2019; 118:169-177.
Aug 1, 2019Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer
Aug 1, 2019Eur J Cancer 2019; 118:169-177
Huober Jens, Hackman John, Dasappa Lokanatha, Ciruelos Eva, Toral Pena Juan Carlos, Adamchuk Hryhoriy, Hickish Tamas, de la Pena Lorena, Jackisch Christian, Gelber Richard D, Piccart-Gebhart Martine, Jouannaud Christelle, Wildiers Hans, Lecocq Christophe, Holmes Eileen, Baselga José, de Azambuja Evandro, Untch Michael, Fumagalli Debora, Sarp Severine, Láng István, Smith Ian, Boyle Frances, Xu Binghe, Di Cosimo Serena